EOLS · XBRL financial data

Evolus financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (EOLS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	56,540	99,673	148,616	202,085	266,274	297,176
Cost of goods and services sold	18,299	43,534	55,887	61,559	83,970	100,069
Gross profit	—	—	89,774	137,571	182,304	197,107
Research and development	1,722	2,064	—	—	—	—
Selling, general and administrative	98,190	112,068	141,840	164,944	198,025	220,786
Operating income (loss)	(153,068)	(44,405)	(65,330)	(49,233)	(34,411)	(32,662)
Interest expense	—	1,396	9,097	13,832	18,735	19,694
Other income (expense)	(10,503)	(1,396)	(9)	696	127	(539)
Income tax expense (benefit)	77	42	95	176	664	677
Net income (loss)	(163,013)	(46,810)	(74,412)	(61,685)	(50,420)	(51,641)
Earnings per share, basic USD per share	(4.83)	(0.94)	(1.33)	(1.08)	(0.81)	(0.80)
Earnings per share, diluted USD per share	(4.83)	(0.94)	(1.33)	(1.08)	(0.81)	(0.80)
Weighted average shares, basic thousands of shares	33,738	49,773	56,065	56,919	62,017	64,469
Weighted average shares, diluted thousands of shares	33,738	49,773	56,065	56,919	62,017	64,469

Fiscal years (EOLS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	102,562	146,256	53,922	62,838	86,952	53,826
Marketable securities	5,000	0	—	—	—	—
Accounts receivable	9,680	14,657	22,448	30,529	47,682	54,697
Inventory	3,354	1,762	18,852	10,998	12,158	26,963
Prepaid and other current assets	7,016	—	—	—	—	—
Total current assets	127,612	178,799	100,802	112,421	151,342	142,917
Property and equipment, net	1,297	1,371	2,616	2,087	3,222	5,371
Right-of-use asset	3,414	2,722	1,947	5,763	7,185	7,133
Goodwill	21,208	21,208	21,208	21,208	21,208	21,208
Total assets	209,068	257,483	177,983	188,998	232,569	225,868
Accounts payable	9,615	6,091	8,935	4,271	9,236	23,360
Accrued liabilities	9,102	29,993	24,794	33,813	40,791	35,591
Total current liabilities	180,248	57,663	46,509	48,291	62,960	75,305
Long-term debt	—	—	—	—	121,506	146,096
Lease liability, non-current	3,147	2,256	1,224	4,810	6,755	6,371
Total liabilities	282,026	175,607	159,484	209,687	227,047	248,974
Accumulated deficit	(376,072)	(422,882)	(497,294)	(558,979)	(609,399)	(661,040)
Total stockholders' equity	(72,958)	81,876	18,499	(20,689)	5,522	(23,106)
Total liabilities and equity	209,068	257,483	177,983	188,998	232,569	225,868
Common shares outstanding (cover page) thousands of shares	43,733	55,694	56,412	57,944	63,587	65,060

Fiscal years (EOLS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(163,013)	(46,810)	(74,412)	(61,685)	(50,420)	(51,641)
Stock-based compensation	10,584	9,576	10,833	16,458	22,254	20,698
Depreciation and amortization	7,027	5,622	3,722	5,133	5,297	7,506
Net cash from operating activities	(57,871)	(33,388)	(84,912)	(34,008)	(17,999)	(42,265)
Purchases of property and equipment	815	393	1,618	473	1,472	3,441
Net cash from investing activities	12,194	4,030	(2,939)	(1,627)	(4,823)	(8,452)
Proceeds from issuing common stock	0	—	0	0	51,211	0
Proceeds from long-term debt	—	—	0	50,000	0	—
Repayments of long-term debt	522	0	—	—	—	—
Net cash from financing activities	38,347	73,052	(4,146)	44,641	47,414	17,337
Net change in cash	(7,330)	43,694	(92,334)	8,916	24,114	(33,126)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Evolus	41,700	77,952	(1,933)*	66.2M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
Avadel Pharmaceuticals	79,813	77,467	22,205*	97.7M	—	Q3 FY25 10-QSep 30, 2025
Xencor	59,622	116,520	2,642*	75.0M	—	Q3 FY26 10-QSep 30, 2026
Savara	41,800	not reported	(29,747)*	205.5M	5.8 quarters	Q2 FY26 10-QJun 30, 2026
Opko Health	384,036	65,414	(36,315)*	742.5M	10.8 quarters	Q3 FY26 10-QSep 30, 2026
Iovance Biotherapeutics	110,768	99,313	(60,841)*	453.0M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Elite Pharmaceuticals	39,416	32,355	10,070	1.1B	—	Q1 FY27 10-QJun 30, 2026
Trevi Therapeutics	54,302	not reported	(17,429)*	142.5M	18.3 quarters	Q2 FY26 10-QJun 30, 2026
Stoke Therapeutics	107,271	11,255	(62,686)*	65.4M	5.2 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.